Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F21%3A73610668" target="_blank" >RIV/61989592:15110/21:73610668 - isvavai.cz</a>

Výsledek na webu

<a href="http://biomed.papers.upol.cz/artkey/bio-202101-0005_mouse-models-of-myeloproliferative-neoplasms-for-pre-clinical-testing-of-novel-therapeutic-agents.php" target="_blank" >http://biomed.papers.upol.cz/artkey/bio-202101-0005_mouse-models-of-myeloproliferative-neoplasms-for-pre-clinical-testing-of-novel-therapeutic-agents.php</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2021.004" target="_blank" >10.5507/bp.2021.004</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents

Popis výsledku v původním jazyce

Myeloproliferative neoplasms (MPN), are clonal hematopoietic stem cell (HSC) disorders driven by gain-of-function mutations in JAK2 (JAK2-V617F), CALR or MPL genes. MPN treatment options currently mainly consist of cytoreductive therapy with hydroxyurea and JAK2 inhibitors such as ruxolitinib and fedratinib. Pegylated interferon-alpha can induce complete molecular remission (CMR) in some MPN patients when applied at early stages of disease. The ultimate goal of modern MPN treatment is to develop novel therapies that specifically target mutant HSCs in MPN and consistently induce CMR. Basic research has identified a growing number of candidate drugs with promising effects in vitro. A first step on the way to developing these compounds into drugs approved for treatment of MPN patients often consists of examining the effects in vivo using pre-clinical mouse models of MPN. Here we review the current state of MPN mouse models and the experimental setup for their optimal use in drug testing. In addition to novel compounds, combinatorial therapeutic approaches are often considered for the treatment of MPN. Optimized and validated mouse models can provide an efficient way to rapidly assess and select the most promising combinations and thereby contribute to accelerating the development of novel therapies of MPN.

Název v anglickém jazyce

Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents

Popis výsledku anglicky

Myeloproliferative neoplasms (MPN), are clonal hematopoietic stem cell (HSC) disorders driven by gain-of-function mutations in JAK2 (JAK2-V617F), CALR or MPL genes. MPN treatment options currently mainly consist of cytoreductive therapy with hydroxyurea and JAK2 inhibitors such as ruxolitinib and fedratinib. Pegylated interferon-alpha can induce complete molecular remission (CMR) in some MPN patients when applied at early stages of disease. The ultimate goal of modern MPN treatment is to develop novel therapies that specifically target mutant HSCs in MPN and consistently induce CMR. Basic research has identified a growing number of candidate drugs with promising effects in vitro. A first step on the way to developing these compounds into drugs approved for treatment of MPN patients often consists of examining the effects in vivo using pre-clinical mouse models of MPN. Here we review the current state of MPN mouse models and the experimental setup for their optimal use in drug testing. In addition to novel compounds, combinatorial therapeutic approaches are often considered for the treatment of MPN. Optimized and validated mouse models can provide an efficient way to rapidly assess and select the most promising combinations and thereby contribute to accelerating the development of novel therapies of MPN.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

<a href="/cs/project/GA17-05988S" target="_blank" >GA17-05988S: Iniciace a progrese myeloproliferativních onemocnění – role patologické aktivace JAK2 v signální dráze erytropoetinového receptoru</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BIOMEDICAL PAPERS-OLOMOUC

ISSN

1213-8118

e-ISSN

—

Svazek periodika

165

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

8

Strana od-do

26-33

Kód UT WoS článku

000629606300005

EID výsledku v databázi Scopus

2-s2.0-85103169659